摘要
背景:在阿尔茨海默病(AD)中抗老年痴呆药物对步态表现的影响存在疑问。meta分析的目的是考虑药物的类型(即乙酰胆碱酯酶抑制剂[AChEIs]与美金刚)和行走状态(即单步和两步)的同时,在AD患者中考察抗痴呆药物对跨步时间平均值和变异系数(CoV)的影响。方法:2015年3月,通过使用医学主题词如“药物制剂”、“治疗用途”、“药物替代”、“药物必需”、“药物,仿制药”、“精神药品”、“精神错乱”、“痴呆”、“遗忘”、“认知障碍”、“步态”、“步态共济失调”、“步态障碍,神经系统”和“步态失调”建立一个没有数据限制的英语和法语医学情报联机系统。固定效应meta分析被用来检测跨步时间平均值和变异系数(CoV)抗痴呆药物相关变化。结果:66篇摘要中,有5篇(7.6%)涉及meta分析。与控制组相比,干预组组间比较的变化表明跨步时间变异系数显著减少,但汇集分析表明平均值没有显着的变化(P > 0.06)。在单步任务条件下,共同使用抗老年性痴呆症的药物AChEIs和美金刚(P < 0.001)时组间在跨步时间参数的改变表明美金刚显著减少(P < 0.001),而在两步任务条件下,只有AChEIs显著提高跨步时间参数(P = 0.002)。结论:通过特定的类效应,根据步行条件和所考虑的跨时间参数的类型,抗老年痴呆药能明显改善步态表现。
关键词: 阿尔茨海默病,抗痴呆药物,双重任务,步态障碍,meta分析,老年人。
Current Alzheimer Research
Title:Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis
Volume: 12 Issue: 8
Author(s): O. Beauchet, C. P. Launay, M Montero-Odasso, C Annweiler and G. Allali
Affiliation:
关键词: 阿尔茨海默病,抗痴呆药物,双重任务,步态障碍,meta分析,老年人。
摘要: Background: The effects of anti-dementia drugs on gait performance in Alzheimer disease (AD) are questionable. The objective of this meta-analysis was to examine the effects of anti-dementia drugs on the mean value and the coefficient of variation (CoV) of stride time among patients with AD while taking into account the type of drugs (i.e., acetylcholinesterase inhibitors [AChEIs] versus memantine) and the walking conditions (i.e., single versus dual-task). Methods: An English and French Medline search was conducted in March 2015, with no limit of date, using the Medical Subject Headings terms “pharmaceutical preparations” combined with terms "Pharmaceutical preparations" OR "Therapeutic uses" OR "Drug substitution" OR "Drugs essential" OR "Drugs, Generic" OR "Psychotropic drugs" combined with "Delirium” OR “Dementia” OR “Amnestic” OR “Cognitive disorders" AND "Gait" OR "Gait Ataxia" OR "Gait disorders, Neurologic" OR “Gait apraxia”. Fixed-effects meta-analyses were used to examine anti-dementia drugs-related changes in mean value and CoV of stride time. Results: Of the 66 identified abstracts, 5 (7.6%) were included in the meta-analysis. Inter-group comparison of between-visit change underscored a significant decrease in CoV of stride time (P<0.004) in intervention group compared to control group, whatever the pooled analysis considered, but no significant change in the mean value (P>0.06). Intra-group changes in stride time parameters following the use of anti-dementia drugs showed a significant decrease for memantine (P<0.001) and while pooling AChEIs and memantine (P<0.001) under single task condition. Under dual task condition, only AChEIs improved significantly stride time parameters (P=0.002). Conclusion: Anti-dementia drugs demonstrated a significant improvement of gait performance with specific class effect depending on the walking conditions and on the type of stride time parameters considered.
Export Options
About this article
Cite this article as:
Beauchet O., P. Launay C., Montero-Odasso M, Annweiler C and Allali G., Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis, Current Alzheimer Research 2015; 12 (8) . https://dx.doi.org/10.2174/1567205012666150710111341
DOI https://dx.doi.org/10.2174/1567205012666150710111341 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Voluntary Running and Environmental Enrichment Restores Impaired Hippocampal Neurogenesis in a Triple Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Rapid HILIC Method for Assay and Dissolution Analysis of Rivastigmine Hydrogen Tartrate from Hydrophilic Matrix
Current Pharmaceutical Analysis Role of Autophagy in Alzheimer’s Disease
Current Enzyme Inhibition Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial: Targeting Cerebral Vascular Injury for Intervention
Current Drug Delivery Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Vitamin B<sub>12</sub> Deficiency Among the Healthy Jordanian Adult Population: Diagnostic Levels, Symptomology and Risk Factors
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research Design, Synthesis and Investigation of New Diphenyl Substituted Pyridazinone Derivatives as Both Cholinesterase and Aβ-Aggregation Inhibitors
Medicinal Chemistry Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data
Current Alzheimer Research Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes
CNS & Neurological Disorders - Drug Targets